T1	p 114 237	patients with acute myeloid leukemia and myelodysplastic syndromes : a Japanese multicenter randomized , controlled study .
T2	p 297 507	prophylactic effects of capsule forms of fluconazole ( n = 110 ) and itraconazole ( n = 108 ) in patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) during and after chemotherapy .
T3	p 734 751	patients with MDS
T4	p 1031 1085	patients with neutrophil counts of > 0.1 x 10 ( 9 ) /L
T5	p 1337 1387	patients with AML or MDS who received chemotherapy
T6	i 33 79	itraconazole capsules and fluconazole capsules
T7	i 338 349	fluconazole
T8	i 366 378	itraconazole
T9	i 574 586	itraconazole
T10	i 649 660	fluconazole
T11	o 84 110	systemic fungal infections
T12	o 541 566	systemic fungal infection
T13	o 669 683	Adverse events
T14	o 832 863	probable or possible infections
T15	o 1122 1144	frequency of infection
T16	o 1450 1473	systemic fungal disease